Improvements in the initial diagnostic workup for bladder cancer
Did you know that you can decrease your patient’s burden and discomfort during the initial workup for bladder cancer with the implementation of urinary biomarkers?
According to the 2024 EAU guidelines [1]:
“Four of the commercially available urine biomarkers, Cx-Bladder™, ADX-Bladder™, Xpert® Bladder and EpiCheck®, although not tested in RCTs, have such high sensitivities and negative predictive values in the referenced studies for HG disease that these biomarkers may approach the sensitivity of cystoscopy. These 4 tests might be used in the initial diagnostic workup to avoid/implement cystoscopy, or in follow-up to replace or postpone cystoscopy.”
Inform your patients and spread the voice with your colleagues to help raise awareness about the availability and benefits of urinary biomarkers
You can download and share with your colleagues our comprehensive slide resource “Biomarkers for NMIBC” and our brochure for healthcare professionals here:
You can also encourage your colleagues to subscribe to BCaMonitor.org and follow us on LinkedIn to receive updates on the latest news about urinary biomarkers for the diagnosis and surveillance of NMIBC and UTUC.
Also the World Bladder Cancer Patient Coalition hosts this special month to raise awareness of the disease. This year the theme “Challenging uncertainty around bladder cancer symptoms” focuses on the correct identification and interpretation of symptoms and the importance of an early diagnosis [2].
The earlier the better
“A timely diagnosis significantly increases the chance of long-term survival and quality of life” [2]
Help the World Bladder Cancer Patient Coalition raise awareness!
Visit the World Bladder Cancer Patient Coalition webpage to discover the initiatives and materials you can use to spark conversations with your colleagues about the importance of an early diagnosis!
References
- Gontero P, Birtle A, Compérat E, et al. European Association of Urology (EAU) guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). Update April 2024. Available at: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/
- https://worldbladdercancer.org/awareness-month/